Clinical Trials Logo

Anlotinib clinical trials

View clinical trials related to Anlotinib.

Filter by:

NCT ID: NCT04116918 Recruiting - NSCLC Stage IV Clinical Trials

Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

Start date: September 1, 2019
Phase:
Study type: Observational

This study is designed to evaluate the efficacy and safety of the combination of Anlotinb and JS001 in EGFR-TKI resistant T790M-negative NSCLC patients.

NCT ID: NCT04012619 Completed - Anlotinib Clinical Trials

Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer

Start date: April 30, 2019
Phase: Phase 1
Study type: Interventional

Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. The ALTER-0303 trial showed that patients with advanced non-small cell lung cancer (NSCLC) who received anlotinib as third-line or further therapy had more survival benefit. Pemetrexed plus platinum-based chemotherapy (AP) was long considered as the first line treatment in non-squamous NSCLC patients with negative driver mutation. In this dose exploration study, the primary objective is to establish the safety profile of anlotinib combined with AP in non-squamous NSCLC patients by identifying dose limiting toxicity (DLT), maximum tolerance dose (MTD), the recommended phase II dose, and schedule. Secondary objective includes the assessment of preliminary antitumor effect.

NCT ID: NCT04002284 Completed - Breast Neoplasm Clinical Trials

Anlotinib in Metastatic HER2 Negative Breast Cancer

Start date: July 12, 2018
Phase: Phase 2
Study type: Interventional

The hypothesis of this study is to discover if the anlotinib can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.

NCT ID: NCT03936452 Completed - Radiotherapy Clinical Trials

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Start date: April 28, 2019
Phase: Phase 2
Study type: Interventional

This study aims to investigate the treatment of previously untreated stage I-II Extranodal NK/T Cell Lymphoma with sintilimab, peg-aspargase and anlotinib, "sandwich" with radiotherapy. The primary endpoint is the complete response rate (CRR) at the end of the treatment, and the second endpoints are CRR after two cycles of the combined regimen (CRR2), overall response rate (ORR) at the end of the treatment, survival time (OS and PFS) and toxicities.

NCT ID: NCT03589950 Not yet recruiting - Lung Neoplasms Clinical Trials

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

Start date: August 1, 2018
Phase: Phase 2
Study type: Interventional

Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to explore Anlotinib for the effectiveness and safety of advanced non-small cell lung cancer who failed first lines of chemotherapy

NCT ID: NCT02072031 Active, not recruiting - Anlotinib Clinical Trials

Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma(RCC)

Start date: December 2013
Phase: Phase 2
Study type: Interventional

Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to compare the efficacy and safety profile between Anlotinib and Sunitinib in patients with advanced Renal Cell Carcinoma(RCC).